Special Issue “Molecular Therapeutics for Diabetes and Related Complications”
Acknowledgments
Conflicts of Interest
List of Contributions
- Muntean, M.; Mărginean, C.; Bernad, E.S.; Bănescu, C.; Nyulas, V.; Muntean, I.E.; Săsăran, V. Adiponectin C1Q and Collagen Domain Containing rs266729, Cy-clin-Dependent Kinase Inhibitor 2A and 2B rs10811661, and Signal Sequence Re-ceptor Subunit 1 rs9505118 Polymorphisms and Their Association with Gesta-tional Diabetes Mellitus: A Case-Control Study in a Romanian Population. Int. J. Mol. Sci. 2025, 26, 1654. https://doi.org/10.3390/ijms26041654.
- Guardiola, M.; Girona, J.; Barroso, E.; García-Altares, M.; Ibarretxe, D.; Plana, N.; Ribalta, J.; Correig, X.; Vázquez-Carrera, M.; Masana, L.; et al. The GDF15 3’ UTR Polymorphism rs1054564 Is Associated with Diabetes and Subclinical Athero-sclerosis. Int. J. Mol. Sci. 2024, 25, 11985. https://doi.org/10.3390/ijms252211985.
- Fernandes Silva, L.; Vangipurapu, J.; Oravilahti, A.; Laakso, M. Novel Metabolites Associated with Decreased GFR in Finnish Men: A 12-Year Follow-Up of the METSIM Cohort. Int. J. Mol. Sci. 2024, 25, 10044. https://doi.org/10.3390/ijms251810044.
- Esteves-Monteiro, M.; Ferreira-Duarte, M.; Vitorino-Oliveira, C.; Costa-Pires, J.; Oliveira, S.; Matafome, P.; Morato, M.; Dias-Pereira, P.; Costa, V.M.; Duarte-Araújo, M. Oxidative Stress and Histomorphometric Remodeling: Two Key Intestinal Features of Type 2 Diabetes in Goto–Kakizaki Rats. Int. J. Mol. Sci. 2024, 25, 12115. https://doi.org/10.3390/ijms252212115.
- Drygalski, K.; Maciejczyk, M.; Miksza, U.; Ustymowicz, A.; Godzień, J.; Buczyńska, A.; Chomentowski, A.; Walczak, I.; Pietrowska, K.; Siemińska, J.; et al. New Ap-plication of an Old Drug: Anti-Diabetic Properties of Phloroglucinol. Int. J. Mol. Sci. 2024, 25, 10291. https://doi.org/10.3390/ijms251910291.
- Mikami-Saito, Y.; Maekawa, M.; Watanabe, M.; Hosaka, S.; Takahashi, K.; Totsune, E.; Arai-Ichinoi, N.; Kikuchi, A.; Kure, S.; Katagiri, H.; et al. Carnitine Deficiency Caused by Salcaprozic Acid Sodium Contained in Oral Semaglutide in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency. Int. J. Mol. Sci. 2025, 26, 2962. https://doi.org/10.3390/ijms26072962.
- Pușcașu, C.; Chiriță, C.; Negreș, S.; Blebea, N.M. Exploring the Therapeutic Poten-tial of N-Methyl-D-Aspartate Receptor Antagonists in Neuropathic Pain Man-agement. Int. J. Mol. Sci. 2024, 25, 11111. https://doi.org/10.3390/ijms252011111.
- Guo, M.; He, F.; Zhang, C. Molecular Therapeutics for Diabetic Kidney Disease: An Update. Int. J. Mol. Sci. 2024, 25, 10051. https://doi.org/10.3390/ijms251810051.
- Keskesiadou, G.-N.; Tsokkou, S.; Konstantinidis, I.; Georgaki, M.-N.; Sioga, A.; Pa-pamitsou, T.; Karachrysafi, S. Endocrine-Disrupting Chemicals and the Develop-ment of Diabetes Mellitus Type 1: A 5-Year Systematic Review. Int. J. Mol. Sci. 2024, 25, 10111. https://doi.org/10.3390/ijms251810111.
References
- Gieroba, B.; Kryska, A.; Sroka-Bartnicka, A. Type 2 diabetes mellitus—Conventional therapies and future perspectives in innovative treatment. Biochem. Biophys. Rep. 2025, 42, 102037. [Google Scholar] [CrossRef] [PubMed]
- Bae, J.H. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab. J. 2025, 49, 386–402. [Google Scholar] [CrossRef] [PubMed]
- Moustafa, B.; Trifan, G. The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases. Curr. Neurol. Neurosci. Rep. 2025, 25, 37. [Google Scholar] [CrossRef] [PubMed]
- Arivarasan, V.K.; Diwakar, D.; Kamarudheen, N.; Loganathan, K. Current approaches in CRISPR-Cas systems for diabetes. Prog. Mol. Biol. Transl. Sci. 2025, 210, 95–125. [Google Scholar] [CrossRef] [PubMed]
- Xie, Y.; Choi, T.; Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 2025, 31, 951–962. [Google Scholar] [CrossRef] [PubMed]
- Rai, P.; Dwibedi, N.; Rowneki, M.; Helmer, D.A.; Sambamoorthi, U. Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus. Am. Health Drug Benefits 2019, 12, 223–231. [Google Scholar] [PubMed]
- Hamblin, P.S.; Wong, R.; Ekinci, E.I.; Fourlanos, S.; Shah, S.; Jones, A.R.; Hare, M.J.L.; Calder, G.L.; Epa, D.S.; George, E.M.; et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. J. Clin. Endocrinol. Metab. 2019, 104, 3077–3087. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ramana, K.V. Special Issue “Molecular Therapeutics for Diabetes and Related Complications”. Int. J. Mol. Sci. 2025, 26, 5585. https://doi.org/10.3390/ijms26125585
Ramana KV. Special Issue “Molecular Therapeutics for Diabetes and Related Complications”. International Journal of Molecular Sciences. 2025; 26(12):5585. https://doi.org/10.3390/ijms26125585
Chicago/Turabian StyleRamana, Kota V. 2025. "Special Issue “Molecular Therapeutics for Diabetes and Related Complications”" International Journal of Molecular Sciences 26, no. 12: 5585. https://doi.org/10.3390/ijms26125585
APA StyleRamana, K. V. (2025). Special Issue “Molecular Therapeutics for Diabetes and Related Complications”. International Journal of Molecular Sciences, 26(12), 5585. https://doi.org/10.3390/ijms26125585